Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Eisenhut, S. Fieseler, H. Sachs, D. Schmid, D. Thieme (Luton, United Kingdom; Munich, Kreischa, Germany). Quantification of long term uptake and metabolism of isoniazid in patients treated for Mycobacterium tuberculosis infection. Eur Respir J 2009; 34: Suppl. 53, 2545

Member's Comments

No comment yet.

Related content which might interest you: Changes in the metabolism of Mycobacterium tuberculosis during the course of TB treatment Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection Year: 2021 Hair-analysis for acetyl-isoniazid/isoniazid ratio and N-acetyl-transferase-2-genotype in patients on treatment for mycobacterium tuberculosis infection Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011 Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis with HPLC technique - comparison to the conventional methods Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005 Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Source: Eur Respir J 2003; 21: 478-482 Year: 2003 The peculiarities of drug susceptibility of M. tuberculosis isolated from patients with late-stage HIV infection Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Risk factors for Mycobacterium tuberculosis infection among contacts of pulmonary tuberculosis patients Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012 Different genetics background of patients with latent tuberculosis infection versus active tuberculosis Source: International Congress 2017 – Asthma genetics and genomics in patients and populations Year: 2017 Drug resistance of Mycobacterium tuberculosis isolated from tuberculosis inflammatory foci Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012 Method of treatment of destructive tuberculosis of single lung with extensively drug resistant mycobacteria tuberculosis Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011 Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis Source: Eur Respir J 2007; 30: 321-332 Year: 2007 Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 Detection of isoniazid or rifampin resistant Mycobacterium tuberculosis in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002 Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries Source: Eur Respir J 2015; 46: 1563-1576 Year: 2015